At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 300 enrolled
Drug / intervention
Bendavia (MTP-131) +1 moredrug
Likely dose
Bendavia (MTP-131) 0.05 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous MTP-131 on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention and Stenting for ST-segment Elevation Myocardial Infarction Infarction
In Brief
A Phase 2 clinical trial evaluating Bendavia (MTP-131) and Placebo for Reperfusion Injury and STEMI. Completed, enrolled 300 participants across 30 sites in 4 countries.
Detailed Summary
The EMBRACE-STEMI trial was a Phase 2a prospective, multicenter, multinational randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and efficacy of IV administered elamipretide (also known as MTP-131, or Bendavia) on a background of standard-of-care therapy for reduction of reperfusion injury in patients with first time acute, anterior wall ST-segment elevation myocardial infarction (STEMI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsReperfusion Injury, STEMI
CountriesGermany, Hungary, Poland, United States
CollaboratorsICON Clinical Research
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
First PostedApr 2012
Primary CompletionNov 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedApr 6, 2012
Enrollment StartApr 1, 2012
Primary CompletionNov 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 14.2 years ago
Interventions
Bendavia (MTP-131)drug
0.05 mg/kg/hr
Placebodrug
Identically appearing placebo